Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.

Date publication

novembre 2015

Journal

British journal of clinical pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DELMER Alain

Tous les auteurs :
Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, Catalani O, Hourcade-Potelleret F, Sayyed P, Badoux X

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25900065

Résumé

The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for patients with chronic lymphocytic leukaemia (CLL).

Mots clés

chronic lymphocytic leukaemia, cyclophosphamide, fludarabine, pharmacokinetics, rituximab, subcutaneous

Référence

Br J Clin Pharmacol. 2015 Nov;80(5):1001-9